To date, clinically approved ICIs targeting PD-1/PD-L1 and CTLA-4 have shown promising efficacy and became the standard treatments for various cancers, such as advanced melanoma, NSCLC, and solid tumors with microsatellite instability (2, 12, 19). Here, PDCD1 is linked to melanoma.